Tandem Diabetes (TNDM) Tops Q4 EPS by 22c, Revenues Beat; Offers FY19 Revenue Guidance Above Consensus

Go back to Tandem Diabetes (TNDM) Tops Q4 EPS by 22c, Revenues Beat; Offers FY19 Revenue Guidance Above Consensus

Tandem Diabetes Care (TNDM) PT Raised to $60 at Cowen Following 'Blowout'

February 27, 2019 8:31 AM EST

Cowen analyst Doug Schenkel raised the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $60.00 (from $40.00) while maintaining a Outperform rating.

The analyst commented, "TNDM posted blowout top to bottom Q4 results. 2019 guidance was also materially ahead of consensus, and still... More

Tandem Diabetes Care (TNDM) PT Raised to $67 at Piper Jaffray

February 27, 2019 3:03 AM EST

Piper Jaffray analyst JP McKim raised the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $67.00 (from $60.00) while maintaining a Overweight rating.

... More

Tandem Diabetes (TNDM) Confirms Succession Plan for CEO and Board

February 26, 2019 4:52 PM EST

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) today announced a succession plan for its chief executive officer (CEO) and select members of its board of directors.

CEO Succession Plan
After nearly 12 years of service as Tandems President and CEO, Kim D. Blickenstaff will transition to a newly-created position of Executive Chairman of the Board of Directors. John F. Sheridan will succeed Mr. Blickenstaff, assuming the role of President and CEO effective March 1, 2019. Mr. Sheridan has served as the Companys Executive Vice President and Chief Operating Officer since April 2013.

John... More